FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Howe Jill Ann				2. Issuer Name and Ticker or Trading Symbol Lineage Cell Therapeutics, Inc. [LCTX]					(Che	eck all application	able)	10% Owner		ner			
(Last) (First) (Middle) C/O LINEAGE CELL THERAPEUTICS 2173 SALK AVENUE, SUITE 200				3. Date of Earliest Transaction (Month/Day/Year) 03/09/2023						X Officer (give title Other (spe below) Chief Financial Officer				,			
(Street) CARLSE		A tate)	92008 (Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year)						Line) <mark>K</mark> Form fil	vidual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)				Execution Date,		Code (Instr. 8)		str. 3, 4 and 9	Beneficia Owned For Reported Transacti	s Form (D) o ollowing (I) (In ion(s)		Direct I Indirect I str. 4)	7. Nature of ndirect Beneficial Dwnership Instr. 4)				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	Conversion Date Execution Date, or Exercise (Month/Day/Year) if any		Cod	ansaction Derivative ode (Instr. Securities		es I (A) sed str.	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amoun of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
				Cod	e V	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares		(Instr. 4)			
Employee Stock Option (Right to Buy)	\$1.46	03/09/2023		A		150,000		(1)	0:	3/09/2033	Common Shares	150,000	\$0.00	150,00	0	D	

Explanation of Responses:

1. One quarter of the options shall vest on March 9, 2024, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment.

/s/ Grant Harbert, as Attorneyin-Fact

03/10/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.